Guide

Pharmaceutical GMP readiness in the United Kingdom

The MHRA regulates medicines in Great Britain (England, Scotland, Wales) and, alongside EU rules under the Windsor Framework, in Northern Ireland. UK GMP is functionally identical to EudraLex Volume 4 — the UK remains a PIC/S member and publishes the 'Orange Guide' (Rules and Guidance for Pharmaceutical Manufacturers and Distributors) as the operational reference. Batch release uses a UK Qualified Person (QP) or, for imports from approved countries, a Responsible Person for Imports (RPi). Distribution follows UK GDP. This guide covers the UK-specific layer over an ICH Q10 PQS.

Start free trial Free trial, no credit card, onboard in days, not months.

Regulator and legal basis

MHRA is the competent authority; it issues Manufacturer's Licences (MIA, MIA(IMP)) and Wholesale Dealer's Licences (WDA(H)). The Human Medicines Regulations 2012 (as amended post-EU exit) are the statutory base. UK GMP follows EudraLex Vol 4; the Orange Guide consolidates GMP, GDP, and UK-specific annexes. NI follows EU rules; GB has diverged on serialization and select market-access elements.

QP and RPi release

A UK QP certifies batches manufactured or imported into the UK, equivalent to EU Annex 16. The Responsible Person for Imports (RPi) is a UK-specific role created post-Brexit for products imported from an EU/EEA listed country already certified by an EU QP — the RPi confirms the EU QP certification, supply-chain integrity, and onward release without repeating full QP certification.

GDP, serialization, and supply

UK GDP mirrors EU GDP; WDA(H) holders must appoint a Responsible Person. FMD ceased to apply in GB on 1 January 2021 — packs intended only for GB no longer require the EMVS-verified unique identifier, although many manufacturers retain the 2D Datamatrix for global packs. NI continues to operate under EU FMD. MHRA has consulted on a UK-specific FMS successor but no statutory scheme is yet in force.

Inspection style and common findings

MHRA inspections use PIC/S classifications (critical/major/other) and publish outcomes via EudraGMDP-equivalent. MHRA is widely seen as the global authority on data integrity — GMP/GDP data integrity guidance (March 2018, refreshed) is referenced internationally and is the most common finding area along with Annex 1 and supplier qualification.

A 90–180 day UK readiness path

Days 0–30: confirm MIA/WDA(H) scope, name QP(s) and RPi (if importing from EU); appoint a Responsible Person for GDP. Days 31–90: close gaps to MHRA data integrity expectations (ALCOA+, audit-trail review, hybrid systems); align Annex 1 CCS; document the supply chain for any imported product. Days 91–180: mock inspection against the Orange Guide, then request MHRA inspection; resolve any deficiencies before the GMP certificate is issued.

Standards covered in this guide

Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.

QP release

QP release means a Qualified Person must personally certify each batch complies with its authorisation and GMP before it can be supplied in the EU or UK.

EU GDP

EU GDP defines how medicines must be stored, handled, and transported so quality and authenticity are preserved from manufacturer to pharmacy, with licensed wholesalers and brokers operating under a robust quality system.

EU GMP Annex 1 Sterile

Annex 1 sets the modern, risk-based standard for sterile manufacturing, requiring a holistic contamination control strategy, robust aseptic operations, and documented evidence that facilities and processes consistently protect patients.

EU Annex 11

Annex 11 defines how GMP computerized systems must be validated, controlled, and monitored to protect product quality and patient safety across the EU, with strong data integrity and lifecycle expectations.

Where this lives in V5 Ultimate

The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.

Modules that do the work

Document control

Versioned SOPs, controlled artwork, periodic review with e-signatures.

QMS

CAPA, deviations, change control, management review wired together.

Audits & CAPA

Findings auto-route to owners with statutory clocks and evidence trail.

Industries this hits hardest

Frequently asked

Is a UK QP the same as an EU QP?

Functionally yes, legally separate post-Brexit. A UK QP must be eligible under UK regulations; EU QP certification is not automatically valid for GB release, and vice versa. NI is the exception — EU rules continue under the Windsor Framework.

When can we use an RPi instead of full QP re-certification?

When importing a product into GB from a country on the MHRA approved-country list (currently EU/EEA member states plus a few others) that has already been QP-certified there. The RPi confirms supply-chain integrity rather than repeating manufacturing/testing certification.

Does FMD still apply in the UK?

Not in GB after 1 January 2021. NI continues under EU FMD. Manufacturers commonly keep the 2D Datamatrix for global packs but it has no legal effect at GB dispense.

How does MHRA differ from FDA in inspection style?

MHRA inspections produce a structured report with critical/major/other findings against the Orange Guide; FDA issues Form 483 observations and may follow with a Warning Letter. MHRA places heavier emphasis on data integrity and PQS governance; FDA emphasizes investigation rigor (211.192) and laboratory controls.

See it on your shop floor.

Free trial, no credit card, onboard in days, not months.

Start free trial See pricing →Browse all resources →